OpportunityTitle: New Approaches for Incorporating Genetic Diversity into Toxicity Testing (R43/R44 Clinical Trial Not Allowed)
AdditionalInformationOnEligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.  Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Description: This Funding Opportunity Announcement (FOA) supports Phase I (R43), Direct to Phase II (R44), and Fast Track (R44) Small Business Innovative Research (SBIR) grant proposals from small businesses concerns (SBCs) to develop resources and approaches, including panels of cells or model organisms, that can better reflect the variability in human populations in chemical toxicity testing. Current toxicology testing is often limited to studies conducted in a small number of laboratory rodent strains, which can fail to identify clinically relevant toxicity if the conventional rodent strain is particularly resistant to the toxic effects of the test compound. Cost-effective screening systems with appropriate throughput are needed to capture the variability in responses to chemical exposure in the human population based on genetic diversity.
GrantorContactEmailDescription: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
GrantorContactText: NIH OER Webmaster&lt;br/&gt;FBOWebmaster@OD.NIH.GOV